Dynamic ploidy changes drive fluconazole resistance in human cryptococcal meningitis
Authors:
- Neil R.H. StoneNSNeil R.H. Stone
- Johanna RhodesJohanna Rhodes
- Matthew C. FisherMFMatthew C. Fisher
- Sayoki MfinangaSMSayoki Mfinanga
- Sokoine KivuyoSKSokoine Kivuyo
- Joan RugemalilaJRJoan Rugemalila
- Ella Shtifman SegalESElla Shtifman Segal
- Leor NeedlemanLNLeor Needleman
- Síle F. MolloySMSíle F. Molloy
- June Kwon-ChungJKJune Kwon-Chung
- Thomas S. HarrisonTHThomas S. Harrison
- William HopeWHWilliam Hope
Top Cited Papers
Open Access
- 28 January 2019
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 129 (3) , 999-1014
Abstract
BACKGROUND. Cryptococcal meningitis (CM) causes an estimated 180,000 deaths annually, predominantly in sub-Saharan Africa, where most patients receive fluconazole (FLC) monotherapy. While relapse after FLC monotherapy with resistant strains is frequently observed, the mechanisms and impact of emergence of FLC resistance in human CM are poorly understood. Heteroresistance (HetR) — a resistant subpopulation within a susceptible strain — is a recently described phenomenon in Cryptococcus neoformans (Cn) and Cryptococcus gattii (Cg), the significance of which has not previously been studied in humans. METHODS. A cohort of 20 patients with HIV-associated CM in Tanzania was prospectively observed during therapy with either FLC monotherapy or in combination with flucytosine (5FC). Total and resistant subpopulations of Cryptococcus spp. were quantified directly from patient cerebrospinal fluid (CSF). Stored isolates underwent whole genome sequencing and phenotypic characterization. RESULTS. Heteroresistance was detectable in Cryptococcus spp. in the CSF of all patients at baseline (i.e., prior to initiation of therapy). During FLC monotherapy, the proportion of resistant colonies in the CSF increased during the first 2 weeks of treatment. In contrast, no resistant subpopulation was detectable in CSF by day 14 in those receiving a combination of FLC and 5FC. Genomic analysis revealed high rates of aneuploidy in heteroresistant colonies as well as in relapse isolates, with chromosome 1 (Chr1) disomy predominating. This is apparently due to the presence on Chr1 of ERG11, which is the FLC drug target, and AFR1, which encodes a drug efflux pump. In vitro efflux levels positively correlated with the level of heteroresistance. CONCLUSION. Our findings demonstrate for what we believe is the first time the presence and emergence of aneuploidy-driven FLC heteroresistance in human CM, association of efflux levels with heteroresistance, and the successful suppression of heteroresistance with 5FC/FLC combination therapy. FUNDING. This work was supported by the Wellcome Trust Strategic Award for Medical Mycology and Fungal Immunology 097377/Z/11/Z and the Daniel Turnberg Travel Fellowship.Keywords
Funding Information
- Wellcome Trust (097377/Z/11/Z.)
This publication has 55 references indexed in Scilit:
- A Prospective Longitudinal Study of the Clinical Outcomes from Cryptococcal Meningitis following Treatment Induction with 800 mg Oral Fluconazole in Blantyre, MalawiPLOS ONE, 2013
- Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungalJournal of Antimicrobial Chemotherapy, 2013
- Titan Cells Confer Protection from Phagocytosis in Cryptococcus neoformans InfectionsEukaryotic Cell, 2012
- Stress Alters Rates and Types of Loss of Heterozygosity in Candida albicansmBio, 2011
- Heteroresistance of Cryptococcus gattii to FluconazoleAntimicrobial Agents and Chemotherapy, 2010
- Combination Flucytosine and High‐Dose Fluconazole Compared with Fluconazole Monotherapy for the Treatment of Cryptococcal Meningitis: A Randomized Trial in MalawiClinical Infectious Diseases, 2010
- Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2010
- Heteroresistance to Fluconazole in Cryptococcus neoformans Is Intrinsic and Associated with VirulenceAntimicrobial Agents and Chemotherapy, 2009
- Comparative hybridization reveals extensive genome variation in the AIDS-associated pathogen Cryptococcus neoformansGenome Biology, 2008
- Results Obtained with Various Antifungal Susceptibility Testing Methods Do Not Predict Early Clinical Outcome in Patients with CryptococcosisAntimicrobial Agents and Chemotherapy, 2006